Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

Benzinga Newsdesk www.benzinga.com Positive 62.3%

Neg 0% Neu 0% Pos 62.3%

Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.